Clippings

Protease inhibitor to raltegravir switch maintains viral suppression, but NRTI resistance lowers efficacy

Date: 22-07-2010

People who switched from a suppressive boosted protease inhibitor to the integrase inhibitor raltegravir (Isentress) generally maintained undetectable viral load with improvements in blood lipid levels, according to a pair of studies presented this week at the Eighteenth International AIDS Conference in Vienna. Once-daily raltegravir, however, did not work as well as twice-daily for people

Click here to read full story provided by NAM

Go back to clippings list.